Aligos Therapeutics
Latest round
- Series B
Last raised
- Dec 2019
Total raised
- $186M
Investors
- 10
About Aligos Therapeutics
Based in California, US, and founded in 2018, Aligos Therapeutics, Inc. develops targeted antiviral therapies for viral infections and liver diseases. The company was co-founded by Lawrence Blatt and Leonid Beigelman. In October 2020, the company went public in Nasdaq Global Market. The company develops therapies for the treatment of chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), and other viral infections.
Who invested in Aligos Therapeutics
10 investors across 2 rounds
See all investors in Aligos Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aligos Therapeutics
Who invested in Aligos Therapeutics?
Aligos Therapeutics has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aligos Therapeutics raised?
Aligos Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aligos Therapeutics last raise money?
Aligos Therapeutics's most recent round on record is a Series B, in Dec 2019.
What does Aligos Therapeutics do?
Based in California, US, and founded in 2018, Aligos Therapeutics, Inc.
Where is Aligos Therapeutics headquartered?
Aligos Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Aligos Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Aligos Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Aligos Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.